CASP1 and metabolic dysfunction-associated steatohepatitis: Clinical evidence reveals substantial increases in caspase-1 and IL-1β activation correlating with NASH progression, where inflammasome triggering exacerbates lipid accumulation, inflammatory responses, and fibrotic transformation [10, 25, 36].